DanCann Pharma A/S signs a Letter of Intent with Canadian Tetra Bio-Pharma Inc. for the exclusive distribution of Reduvo™ Adversa[® ]and Qixleef™ in Scandinavia and Germany
COPENHAGEN, Denmark, 25 February 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) is pleased to announce the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa[®] and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.Pursuant to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for the products, Reduvo™ Adversa® and Qixleef™. In addition, the agreement covers